Eurofins Built Environment Testing Expands AIHA LAP, LLC Certification for Industrial Hygiene Analysis

PASADENA, Texas–(BUSINESS WIRE)–Eurofins J3 Resources, part of Eurofins Built Environment Testing US, is proud to announce it has been granted AIHA LAP, LLC accreditation as part of a National expansion program of Industrial Hygiene credentials. Eurofins J3 Resources’ industrial hygiene service offering to Texas, Louisiana and Gulf Coast based refineries and chemical plants has been … [Read more…]

Sparrow Pharmaceuticals to Present New Clinical Pharmacology Data on SPI-62 at the Endocrine Society (ENDO) 2022 Annual Conference

PORTLAND, Ore.–(BUSINESS WIRE)–Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new clinical pharmacology data at the Endocrine Society (ENDO) 2022 Annual Conference on its candidate, SPI-62, an HSD-1 inhibitor. Sparrow will present the data during an in-person … [Read more…]

Wugen Presents New Preclinical Data Demonstrating Enhanced Anti-Tumor Activity of WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress

— WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment (TME) immunosuppression relative to conventional natural killer (NK) cells — — WU-NK-101 demonstrated robust anti-tumor activity in vitro and in vivo in preclinical models of acute myeloid leukemia (AML) — — Data support the development of WU-NK-101 for AML and solid tumor indications — … [Read more…]

Global Drug Delivery Partnering Deals Terms and Agreements Analysis Report/Directory 2015-2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Drug Delivery Partnering Terms and Agreements 2015-2022” report has been added to ResearchAndMarkets.com’s offering. The Global Drug Delivery Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the Drug Delivery partnering deals and agreements entered into by the worlds leading healthcare companies. One of the key highlights of … [Read more…]

Global Diagnostics Partnering Terms and Agreements Report/Directory 2015-2022: Access to 3,200+ Deals Signed by the World’s Leading Biopharma Companies – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Diagnostics Partnering Terms and Agreements 2015-2022” report has been added to ResearchAndMarkets.com’s offering. The Global Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 3,200 Diagnostics deals. The report provides a detailed understanding and analysis of how and why companies enter Diagnostics partnering … [Read more…]

Global Medical REIT Inc. Board Declares 2022 Second Quarter Common and Preferred Dividends

BETHESDA, Md.–(BUSINESS WIRE)–Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), a net-lease medical office real estate investment trust (REIT) that acquires purpose-built healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share, announced today that its Board of Directors (“Board”) has declared the Company’s 2022 second … [Read more…]

Pendulum Therapeutics Releases In-Depth Profile of Akkermansia muciniphila, a Key Strain Forging a Path for the Future of Probiotics

New publication reveals how a keystone strain exerts potential to impact a spectrum of health outcomes through immune and metabolic regulation SAN FRANCISCO–(BUSINESS WIRE)–Pendulum Therapeutics, the biotech company pioneering the next frontier of health through its microbiome-targeted products, today announced the release of its whitepaper, An In-Depth Profile of the Gut Commensal Akkermansia muciniphila, a … [Read more…]

BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress

Clinical data and patient-reported outcomes across extensive clinical development program for zanubrutinib (BRUKINSA®) reinforce its potential across B-cell malignancies Long-term safety and efficacy results from the Phase 3 ASPEN trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Oral presentation for the Phase 2 ROSEWOOD trial of zanubrutinib plus obinutuzumab in follicular lymphoma New … [Read more…]

Mednow to Present at Gravitas’ 3rd Los Angeles Summit

TORONTO–(BUSINESS WIRE)–Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy, is pleased to announce it will be presenting at Gravitas Securities Inc.’s (“Gravitas”) 3rd Los Angeles Summit, which will be taking place at the Beverly Hills Hotel from June 21st to June 24th, 2022, in Beverly Hills, California. Gravitas’ 3rd Los Angeles … [Read more…]

Iveric Bio Announces Presentation of Post-Hoc Analysis at Macula Society from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

PARSIPPANY, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) announced today a post-hoc analysis from the Zimura® (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence Tomography (OCT) image analysis to examine the effect of Zimura on change in Ellipsoid Zone (EZ) integrity and growth of OCT-measured geographic atrophy (GA), and to examine the correlation between … [Read more…]